Now showing items 1-20 of 50

    • 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. 

      Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; Wai, PT; Maguire, SL; Barker, HE; Morrison, E; Kriplani, D; Yu, L; Gibson, A; Falgari, G; Brennan, K; Farnie, G; Buus, R; Marlow, R; Novo, D; Knight, E; Guppy, N; Kolarevic, D; Susnjar, S; Milijic, NM; Naidoo, K; Gazinska, P; Roxanis, I; Pancholi, S; Martin, L-A; Holgersen, EM; Cheang, MCU; Noor, F; Postel-Vinay, S; Quinn, G; McDade, S; Krasny, L; Huang, P; Daley, F; Wallberg, F; Choudhary, JS; Haider, S; Tutt, AN; Natrajan, R (2021-01-28)
      Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...
    • Advances in mass spectrometry based strategies to study receptor tyrosine kinases. 

      Vyse, S; Desmond, H; Huang, PH (2017-03)
      Receptor tyrosine kinases (RTKs) are key transmembrane environmental sensors that are capable of transmitting extracellular information into phenotypic responses, including cell proliferation, survival and metabolism. ...
    • Advances in the proteomic profiling of the matrisome and adhesome. 

      Krasny, L; Huang, PH
      INTRODUCTION: The matrisome and adhesome comprise proteins that are found within or are associated with the extracellular matrix (ECM) and adhesion complexes, respectively. Interactions between cells and their microenvironment ...
    • Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase. 

      Corallino, S; Iwai, LK; Payne, LS; Huang, PH; Sacco, F; Cesareni, G; Castagnoli, L (2016-09)
      The phosphatase SHP-2 plays an essential role in growth factor signaling and mutations in its locus is the cause of congenital and acquired pathologies. Mutations of SHP-2 are known to affect the activation of the RAS ...
    • Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. 

      Smrke, A; Gennatas, S; Huang, P; Jones, RL (2020-08)
      Gastrointestinal stromal tumors (GIST) can be molecularly classified based on different subtypes including mutations in <i>KIT</i> and <i>PDGFRA</i>. Patients with <i>PDGFRA</i> mutations are an important subgroup that ...
    • Clinical and Molecular Spectrum of Liposarcoma. 

      Lee, ATJ; Thway, K; Huang, PH; Jones, RL (2018-01)
      Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ...
    • Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit. 

      Cojocaru, E; Palahepitiva Gamage, G; Butler, J; Barton, DP; Thway, K; Fisher, C; Messiou, C; Miah, AB; Zaidi, S; Gennatas, S; Benson, C; Huang, P; Jones, RL
      Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ...
    • Comparative proteomic assessment of matrisome enrichment methodologies. 

      Krasny, L; Paul, A; Wai, P; Howard, BA; Natrajan, RC; Huang, PH (2016-11)
      The matrisome is a complex and heterogeneous collection of extracellular matrix (ECM) and ECM-associated proteins that play important roles in tissue development and homeostasis. While several strategies for matrisome ...
    • Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. 

      Krasny, L; Huang, PH (2020-10-09)
      Data-independent acquisition mass spectrometry (DIA-MS) is a next generation proteomic methodology that generates permanent digital proteome maps offering highly reproducible retrospective analysis of cellular and tissue ...
    • Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining. 

      Cook, R; Zoumpoulidou, G; Luczynski, MT; Rieger, S; Moquet, J; Spanswick, VJ; Hartley, JA; Rothkamm, K; Huang, PH; Mittnacht, S (2015-03-26)
      Deficiencies in DNA double-strand break (DSB) repair lead to genetic instability, a recognized cause of cancer initiation and evolution. We report that the retinoblastoma tumor suppressor protein (RB1) is required for DNA ...
    • Drug repositioning in sarcomas and other rare tumors. 

      Lee, ATJ; Huang, PH; Pollack, SM; Jones, RL (2016-04)
    • Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. 

      Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; Vyse, S; Luczynski, MT; Crosier, S; Ryall, KA; Holmes, K; Payne, LS; Daley, F; Wai, P; Jenks, A; Tanos, B; Tan, A-C; Natrajan, RC; Williamson, D; Huang, PH (2016-10)
      Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ...
    • Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. 

      Cojocaru, E; Thway, K; Fisher, C; Messiou, C; Zaidi, S; Miah, AB; Benson, C; Gennatas, S; Huang, P; Jones, RL (2020-12)
      Background/aim Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant ...
    • Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. 

      Stacchiotti, S; Miah, AB; Frezza, AM; Messiou, C; Morosi, C; Caraceni, A; Antonescu, CR; Bajpai, J; Baldini, E; Bauer, S; Biagini, R; Bielack, S; Blay, JY; Bonvalot, S; Boukovinas, I; Bovee, JVMG; Boye, K; Brodowicz, T; Callegaro, D; De Alava, E; Deoras-Sutliff, M; Dufresne, A; Eriksson, M; Errani, C; Fedenko, A; Ferraresi, V; Ferrari, A; Fletcher, CDM; Garcia Del Muro, X; Gelderblom, H; Gladdy, RA; Gouin, F; Grignani, G; Gutkovich, J; Haas, R; Hindi, N; Hohenberger, P; Huang, P; Joensuu, H; Jones, RL; Jungels, C; Kasper, B; Kawai, A; Le Cesne, A; Le Grange, F; Leithner, A; Leonard, H; Lopez Pousa, A; Martin Broto, J; Merimsky, O; Merriam, P; Miceli, R; Mir, O; Molinari, M; Montemurro, M; Oldani, G; Palmerini, E; Pantaleo, MA; Patel, S; Piperno-Neumann, S; Raut, CP; Ravi, V; Razak, ARA; Reichardt, P; Rubin, BP; Rutkowski, P; Safwat, AA; Sangalli, C; Sapisochin, G; Sbaraglia, M; Scheipl, S; Schöffski, P; Strauss, D; Strauss, SJ; Sundby Hall, K; Tap, WD; Trama, A; Tweddle, A; van der Graaf, WTA; Van De Sande, MAJ; Van Houdt, W; van Oortmerssen, G; Wagner, AJ; Wartenberg, M; Wood, J; Zaffaroni, N; Zimmermann, C; Casali, PG; Dei Tos, AP; Gronchi, A (2021-06-02)
      Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a ...
    • The evolving management of epithelioid sarcoma. 

      Alves, A; Constantinidou, A; Thway, K; Fisher, C; Huang, P; Jones, RL (2021-07-18)
    • Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 

      Vyse, S; Howitt, A; Huang, PH (2017-06)
      Despite the recent approval of third-generation therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small cell lung cancer. Conceptually, synthetic lethality ...
    • Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. 

      Harrison, PT; Huang, PH (2018-10-26)
      Drug resistance remains one of the greatest challenges facing precision oncology today. Despite the vast array of resistance mechanisms that cancer cells employ to subvert the effects of targeted therapy, a deep understanding ...
    • Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas 

      Napolitano, A; Ostler, AE; Jones, RL; Huang, PH
      <jats:p>Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) ...
    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; White, IJ; Benjamin, AC; Dertschnig, S; Horsnell, HL; Kriston-Vizi, J; Burden, JJ; Huang, PH; Tape, CJ; Acton, SE (2019-11)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...
    • Future Directions in the Treatment of Osteosarcoma. 

      Smrke, A; Anderson, PM; Gulia, A; Gennatas, S; Huang, PH; Jones, RL (2021-01-15)
      Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy ...